Close Menu

NEW YORK – Fulgent Genetics intends to sell $22.5 million in shares of its common stock, the firm said in a regulatory document on Friday.

Separately, the company said it entered an agreement with investment bank Piper Jaffray to sell $30 million of its shares from time to time. The $22.5 million offering disclosed in a prospectus filed last week with the US Securities and Exchange Commission is part of that deal. It said that proceeds will go toward working capital and general corporate purposes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.